Claims for Patent: 9,090,689
✉ Email this page to a colleague
Summary for Patent: 9,090,689
Title: | Use of TNF.alpha. inhibitor for treatment of psoriasis |
Abstract: | The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. |
Inventor(s): | Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Banerjee; Subhashis (Princeton, NJ), Taylor; Lori K. (Boston, MA), Spiegler; Clive E. (Skillman, NJ), Tracey; Daniel E. (Harvard, MA), Chartash; Elliot K. (Marietta, GA), Barchuk; William T. (San Diego, CA), Yan; Philip (Vernon Hills, IL), Murtaza; Anwar (Westborough, MA), Salfeld; Jochen G. (North Grafton, MA), Fischkoff; Steven A. (Short Hills, NJ), Granneman; George R. (Marco Island, FL) |
Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 14/681,704 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,090,689 |
Patent Claims: | 1. A method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and subcutaneously
administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.
2. The method of claim 1, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 3. The method of claim 2, wherein said vessels each contains 40 mg of adalimumab. 4. The method of claim 1, wherein said vessels are syringes. 5. The method of claim 4, wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml. 6. The method of claim 5, wherein said syringes each contains 40 mg of adalimumab. 7. A method of preparing adalimumab for treating moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and providing said adalimumab for treatment, wherein said treatment comprises subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week. 8. The method of claim 7, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 9. The method of claim 8, wherein said vessels each contains 40 mg of adalimumab. 10. The method of claim 7, wherein said vessels are syringes. 11. The method of claim 10, wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml. 12. The method of claim 11, wherein said syringes each contains 40 mg of adalimumab. 13. The method of claim 7, wherein at least 5% body surface area (BSA) of the patient is affected by the psoriasis. 14. The method of claim 13, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 15. The method of claim 14, wherein each said vessels are syringes and each contains 40 mg of adalimumab. 16. The method of claim 7, wherein said patient has both psoriasis and psoriatic arthritis and achieves at least a 75% reduction in Psoriasis Area and Severity Index (PASI) score at week 12 of the treatment. 17. The method of claim 16, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 18. The method of claim 17, wherein each said vessels are syringes and each contains 40 mg of adalimumab. 19. The method of claim 7, wherein said patient has both psoriasis and psoriatic arthritis and achieves at least a Physician Global Assessment (PGA) score of clear or almost clear at week 12 of the treatment. 20. The method of claim 19, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 21. The method of claim 20, wherein each said vessels are syringes and each contains 40 mg of adalimumab. |
Details for Patent 9,090,689
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2021-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.